SU1273977A1 - Method of modelling sepsis - Google Patents

Method of modelling sepsis Download PDF

Info

Publication number
SU1273977A1
SU1273977A1 SU843792558A SU3792558A SU1273977A1 SU 1273977 A1 SU1273977 A1 SU 1273977A1 SU 843792558 A SU843792558 A SU 843792558A SU 3792558 A SU3792558 A SU 3792558A SU 1273977 A1 SU1273977 A1 SU 1273977A1
Authority
SU
USSR - Soviet Union
Prior art keywords
sepsis
suspension
development
foci
culture
Prior art date
Application number
SU843792558A
Other languages
Russian (ru)
Inventor
Лев Львович Шимкевич
Владимир Григорьевич Тепляков
Евгений Дмитриевич Вовк
Original Assignee
Институт Хирургии Им.А.В.Вишневского
Всесоюзный научный центр хирургии АМН СССР
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Институт Хирургии Им.А.В.Вишневского, Всесоюзный научный центр хирургии АМН СССР filed Critical Институт Хирургии Им.А.В.Вишневского
Priority to SU843792558A priority Critical patent/SU1273977A1/en
Application granted granted Critical
Publication of SU1273977A1 publication Critical patent/SU1273977A1/en

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относитс  к медицине , в частности к хирургии, может быть применено в клиниках и лаборатори х в профилактике, ранней диагностике и лечении заболевани  сепсисом. Цель изобретени  - создание модели сепсиса с про влением метастатических очагов во внутренних органах. Дл  этого культуру стафилококка выращивали при 37°С на м со-пептонном агаре. Содержание микробов во взвеси определ ют по оптическому стандарту мутности, что составл ет 10 - 10 микробных тел в 1 мл. Крысам массой 120-350 г внутримьшечно однократно .ввод т в зависимости от массы 0,15 0 ,3 мл взвеси суточной культуры стафилококка в 10%-ном растворе CaCl. Предлагаемый способ вызывает развитие местного гнойного очага, бактериемию , вторичные пиемические очаги и дистрофические изменени  во внуто SS ренних органах, сопровождающиес  летальностью , т.е. вызывают развитие комплекса критериев, характеризующих заболевание сепсисом у человека.The invention relates to medicine, in particular to surgery, can be applied in clinics and laboratories in the prevention, early diagnosis and treatment of sepsis. The purpose of the invention is to create a model of sepsis with the appearance of metastatic foci in the internal organs. For this, staphylococcal culture was grown at 37 ° C on m-peptone agar. The microbial content of the suspension is determined by the optical turbidity standard, which is 10 to 10 microbial cells per ml. Rats weighing 120-350 g were intramuscularly injected once depending on the weight of 0.15-0.3 ml suspension of the daily culture of staphylococcus in 10% CaCl solution. The proposed method causes the development of a local suppurative focus, bacteremia, secondary pyemichesky foci and dystrophic changes in the SS of the renal organs accompanied by mortality, i.e. cause the development of a set of criteria that characterize the disease sepsis in humans.

Description

ГОGO

N|N |

СОWITH

соwith

vlvl

«-4"-four

Claims (1)

Формула изобретенияClaim Способ моделирования сепсиса путем внутримышечного введения взвеси микробов в организм животных, отличающийся тем, что, с целью моделирования сепсиса с проявлением метастатических очагов во внутренних органах, взвесь микробов вводят в растворе хлористого кальция.A method for simulating sepsis by intramuscular injection of microbial suspension into an animal organism, characterized in that, in order to simulate sepsis with the manifestation of metastatic foci in internal organs, microbial suspension is injected in a solution of calcium chloride.
SU843792558A 1984-07-23 1984-07-23 Method of modelling sepsis SU1273977A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU843792558A SU1273977A1 (en) 1984-07-23 1984-07-23 Method of modelling sepsis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU843792558A SU1273977A1 (en) 1984-07-23 1984-07-23 Method of modelling sepsis

Publications (1)

Publication Number Publication Date
SU1273977A1 true SU1273977A1 (en) 1986-11-30

Family

ID=21139209

Family Applications (1)

Application Number Title Priority Date Filing Date
SU843792558A SU1273977A1 (en) 1984-07-23 1984-07-23 Method of modelling sepsis

Country Status (1)

Country Link
SU (1) SU1273977A1 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hermeck A.S. е.а. Archive surgery, 1969, 197, p.1973. *

Similar Documents

Publication Publication Date Title
DE69022290D1 (en) Live vaccines.
FR2415105A1 (en) N-METHYL ESTERS OF HYDANTOIN, THEIR PREPARATION AND THEIR APPLICATION AS INSECTICIDES OR ACARICIDES
AT398781B (en) IMMORTAL CELL LINE AND THEIR USE
Stratton et al. Red cell agglutinability affected by disease
ATE175112T1 (en) USE OF TAURINE FOR PRODUCING A MEDICATION FOR STIMULATING MYELOPEROXIDASE ACTIVITY
Herrell et al. Experimental and clinical studies on gramicidin
FR2289498A1 (en) 1- (BIS-TRIFLUOROMETHYLPHENYL) -2-OXO-PYRROLIDINE-4-CARBOXYL ACID DERIVATIVES, USEFUL AS PLANT GROWTH REGULATORS AND AS HERBICIDES
NO180544C (en) Process for Preparation of Human IL-3 (Pro-8), Expression Vector, Vector and Transformed Living Host Cell
ZA875551B (en) Monoclonal antibodies and their production and use
SU1273977A1 (en) Method of modelling sepsis
FR2418797A1 (en) NEW HETEROCYCLIC ACETIC ACID DERIVATIVES, THEIR PROCESS FOR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
FI801026A (en) DESINFEKTIONSAEMNE FOER JUVRER SAMT FOERFARANDE FOER DESINFEKTION AV SPENAR
ATE125870T1 (en) HIV-SPECIFIC MONOCLONAL ANTIBODIES AND HYBRIDOMAS FOR THEIR PRODUCTION.
FR2374302A1 (en) NEW HALOGENETHYL-SULPHONES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS PLANT GROWTH SUBSTANCES
TR23988A (en) ARILOXIFENYL-THIOROURERS
GB1491816A (en) Urokinase production
SE8500093L (en) urokinase derivatives
ATE74708T1 (en) HERBICIDAL PROCESS USING DIFLUFENICAN.
Cody et al. Protective anti-lipopolysaccharide monoclonal antibodies inhibit tumor necrosis factor production
GB1319772A (en) Succinimides
KR850001531A (en) Hybridoma cell line producing monotrophic antibodies and monotrophic antibodies that recognize the common structure of the light chain of human internal leukocyte-2 (TCGF) and human immunoglobulin
ES2123741T3 (en) DERIVATIVES OF BENCIMIDAZOLE, ITS PREPARATION AND USE.
DK612188D0 (en) ANTIBIOTIC A / 16686 FACTORS A'1, A'2 AND A'3, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL PREPARATION CONTAINING SUCH RELATIONSHIPS
US1990982A (en) Biological medicament
IL73657A (en) N-(1-oxo-3beta-hydroxy-6-phenoxy-indan-5-yl)-methane sulfonamide derivatives,process for their preparation and pharmaceutical compositions containing the same